title: The Higher Response of Vascular Endothelial Growth Factor and Angiotensin-II to Human Chorionic Gonadotropin in Women with Polycystic Ovary Syndrome.
abstract: BACKGROUND
  This research investigated the response of vascular active factors, vascular endothelial growth factor (VEGF) and angiotensin-II (AT-II) to ovarian stimulation during 24 hours in patients with polycystic ovary syndrome (PCOS).
  
  
  METHODS
  In this clinical trial study, 52 patients with PCOS and 8 control cases were stimulated with human chorionic gonadotropin (HCG) on the 4(th) to 7(th) day of the patients' natural or induced menstrual cycles. We measured VEGF and AT-II by radioimmunoassay before the injection (0 hour) and 3, 8, 12, 18 and 24 hours after the stimulation.
  
  
  RESULTS
  After ovarian stimulation, there was substantially higher level of VEGF in typical PCOS patients than the other three groups at the 3 hour time point (p<0.05), while there were no significant differences in VEGF at all the other time points among the four groups. As for AT-II, before and at all time points after the ovarian stimulation, it seemed that the AT-II levels in patients' sera with different phenotypes of PCOS by the Rotterdam criteria were all higher than in the control group although the differences were not statistically significant. The level of AT-II in typical PCOS patients was also significantly higher than the other three groups at the 3 hour time point (p<0.05), while no significant differences at all the other time points among the four groups were observed.
  
  
  CONCLUSIONS
  The response to the stimulation varied among patients with different phenotypes of PCOS according to the Rotterdam criteria. Serum VEGF and AT-II were possible contributors to an increased risk of developing ovarian hyperstimulation syndrome (OHSS) in patients with typical PCOS during the early follicular phase (3 hours) after ovarian stimulation (
  
  
  BACKGROUND
  NCT02265861).
authors.affiliation: Department of Gynecological Oncology Surgery, Jiangsu Cancer Hospital and Institute, Nanjing 210009, China.
authors.forename: Junwei
authors.initials: J
authors.lastname: Qu
authors.affiliation: Translational Medicine Center and Jiangsu Key Laboratory of Molecular Medicine, Medical School of Nanjing University, Nanjing 210093, China.
authors.forename: Yena
authors.initials: Y
authors.lastname: Che
authors.affiliation: Translational Medicine Center and Jiangsu Key Laboratory of Molecular Medicine, Medical School of Nanjing University, Nanjing 210093, China.
authors.forename: Pei
authors.initials: P
authors.lastname: Xu
authors.affiliation: Translational Medicine Center and Jiangsu Key Laboratory of Molecular Medicine, Medical School of Nanjing University, Nanjing 210093, China.
authors.forename: Yanjie
authors.initials: Y
authors.lastname: Xia
authors.affiliation: Department of Obstetrics and Gynecology, The First Affiliated Hospital, Heilongjiang University of Chinese Medicine, Harbin 150040, China.
authors.forename: Xiaoke
authors.initials: X
authors.lastname: Wu
authors.affiliation: Translational Medicine Center and Jiangsu Key Laboratory of Molecular Medicine, Medical School of Nanjing University, Nanjing 210093, China.
authors.forename: Yong
authors.initials: Y
authors.lastname: Wang
keywords: Angiotensin-II; Ovarian Hyperstimulation Syndrome; Polycystic Ovary Syndrome; Vascular Endothelial Growth Factor